Published in Acta Med Scand Suppl on January 01, 1979
Hypotension and environmental noise: a replication study. Int J Environ Res Public Health (2014) 0.75
Molecular analysis of commensal host-microbial relationships in the intestine. Science (2001) 12.04
Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) Lancet (1991) 9.57
Fibronectin binding mediated by a novel class of surface organelles on Escherichia coli. Nature (1989) 5.09
Chromosomal loci of Neurospora crassa. Microbiol Rev (1982) 4.26
Coronary heart-disease after treatment of hypertension. Lancet (1978) 3.78
Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody). Leukemia (2007) 3.33
Effects of clonidine withdrawal: possible mechanisms and suggestions for management. Br Med J (1973) 2.87
1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization. Clin Exp Hypertens (1999) 2.72
Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer (2007) 2.36
Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension (1998) 2.31
Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors. BMJ (1992) 2.31
Arthrographic studies of wrist ganglions. J Bone Joint Surg Am (1971) 2.19
Pharmacokinetic studies on the selective beta1-receptor antagonist metoprolol in man. J Pharmacokinet Biopharm (1974) 2.18
Blood pressure crisis following withdrawal of clonidine (Catapres, Catapresan), with special reference to arterial and urinary catecholamine levels, and suggestions for acute management. Am Heart J (1973) 2.17
Home blood pressure determination. Value in borderline ("labile") hypertension. JAMA (1974) 2.16
Initial clinical experience with I.C.I. 66.082, a new beta-adrenergic blocking agent, in hypertension. Acta Med Scand (1973) 2.10
The 1993 guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. Blood Press (1993) 2.03
A survey of the pharmacological properties of metoprolol in animals and man. Acta Pharmacol Toxicol (Copenh) (1975) 2.01
Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol (2001) 1.94
Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer (2003) 1.86
Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens (1992) 1.73
The Hypertension Optimal Treatment (HOT) Study--patient characteristics: randomization, risk profiles, and early blood pressure results. Blood Press (1994) 1.70
[There is no reason to avoid calcium antagonists in hypertension]. Lakartidningen (1996) 1.62
Metabolism of metoprolol-(3-h) in man, the dog and the rat. Acta Pharmacol Toxicol (Copenh) (1975) 1.61
Blood glycoprotein levels in diabetes mellitus. Diabetologia (1976) 1.58
Initial clinical experience with ICI 141,292 (Visacor), a new selective beta 1-adrenoceptor blocker with ISA--a multicentre trial in 59 patients. Br J Clin Pharmacol (1984) 1.53
Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial. Lancet (2001) 1.52
Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors. BMJ (1994) 1.52
Capsaicin-induced cough in humans. Am Rev Respir Dis (1992) 1.49
Reversal of cardiovascular structural changes when treating essential hypertension. The importance of the renin-angiotensin-aldosterone system. Am J Hypertens (1992) 1.48
Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment. J Hypertens (2000) 1.48
A 5-year prospective, observational study of the withdrawal of antihypertensive treatment in elderly people. J Intern Med (1994) 1.46
Risk factors associated with alterations in carotid intima-media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis. J Hypertens (1998) 1.46
Organization and efficacy of an out-patient hypertension clinic. Acta Med Scand (1978) 1.45
Noise as a contributory factor in the development of elevated arterial pressure. A study of the mechanisms by which noise may raise blood pressure in man. Acta Med Scand (1980) 1.42
Controlled study of atenolol in treatment of hypertension. Br Med J (1975) 1.41
Test characteristics of the Hopkins Symptom Check List-25 (HSCL-25) in Sweden, using the Present State Examination (PSE-9) as a caseness criterion. Soc Psychiatry Psychiatr Epidemiol (1993) 1.36
Unique splicing pattern of the TCF7L2 gene in human pancreatic islets. Diabetologia (2009) 1.33
Twice-daily propranolol treatment for hypertension. Lancet (1971) 1.31
Hemodynamic effects of acute and prolonged beta-adrenergic blockade in essential hypertension. Acta Med Scand (1974) 1.28
Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther (2000) 1.28
Endemic versus non-endemic gonorrhoea in Stockholm: results of contact tracing. Int J STD AIDS (1993) 1.21
A comparison of the antihypertensive effect of atenolol (ICI 66 082) and propranolol. Eur J Clin Pharmacol (1976) 1.21
Malignant hypertension--improving prognosis in a rare disease. Acta Med Scand (1979) 1.21
Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. J Hypertens (2001) 1.19
Propranolol given twice daily in hypertension. Acta Med Scand (1973) 1.19
Progressive bilateral thinning of the parietal bones. Skeletal Radiol (1982) 1.18
Serotoninergic mechanisms in hypertension. Focus on the effects of ketanserin. Hypertension (1988) 1.17
Haemodynamic effects of carvedilol, a new beta-adrenoceptor blocker and precapillary vasodilator in essential hypertension. J Hypertens (1984) 1.16
Increased serum concentrations of cartilage oligomeric matrix protein. A prognostic marker in early rheumatoid arthritis. Br J Rheumatol (1992) 1.15
STOP-Hypertension 2: a prospective intervention trial of "newer" versus "older" treatment alternatives in old patients with hypertension. Swedish Trial in Old Patients with Hypertension. Blood Press (1993) 1.15
STOP-Hypertension--preliminary communication from the pilot study of the Swedish Trial in Old Patients with Hypertension. J Hypertens Suppl (1987) 1.14
Regional haemodynamic effects of endothelin-1 in rat and man: unexpected adverse reaction. J Hypertens (1990) 1.13
The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol (2001) 1.12
The search for putative unifying genetic factors for components of the metabolic syndrome. Diabetologia (2008) 1.11
Breast cancer screening with mammography: a population-based, randomized trial with mammography as the only screening mode. Radiology (1979) 1.11
Erythrocyte gangliosides act as receptors for Neisseria subflava: identification of the Sia-1 adhesin. Infect Immun (1990) 1.10
Lake secondary production fueled by rapid transfer of low molecular weight organic carbon from terrestrial sources to aquatic consumers. Ecol Lett (2010) 1.10
Beta-adrenergic blockade in essential hypertension. Effects of propranolol on hemodynamic parameters and plasma renin activity. Acta Med Scand Suppl (1973) 1.10
Objective social outcomes index (SIX): a method to summarise objective indicators of social outcomes in mental health care. Acta Psychiatr Scand (2008) 1.10
Prolonged exposure to a stressful stimulus (noise) as a cause of raised blood-pressure in man. Lancet (1977) 1.09
Hypertension in the elderly. Hypertension seminars at Ostra Hospital, Göteborg, Sweden. Acta Med Scand (1981) 1.09
Antihypertensive mechanism of beta-adrenoceptor antagonism--the role of beta 2-blockade. J Hypertens Suppl (1983) 1.08
Binding of two adrenergic beta-receptor antagonists, alprenolol and H 93-26, to human serum proteins. Acta Pharm Suec (1974) 1.07
Relation of maternal blood pressure during pregnancy to birth weight and blood pressure in children. The Hypertension in Pregnancy Offspring Study. J Intern Med (1994) 1.07
Does drug treatment improve survival in mild-to-moderate hypertension? J Hypertens (1995) 1.07
Changes in glycosylation of human bile-salt-stimulated lipase during lactation. Arch Biochem Biophys (2000) 1.07
Interaction between prenatal growth and high-risk genotypes in the development of type 2 diabetes. Diabetologia (2009) 1.07
Diet and the risk of papillary and follicular thyroid carcinoma: a population-based case-control study in Sweden and Norway. Cancer Causes Control (1997) 1.06
Ketanserin in hypertension. Early clinical evaluation and dose finding study of a new 5-HT2 receptor antagonist. Acta Med Scand (1983) 1.05
Long-term effects of losartan on blood pressure and left ventricular structure in essential hypertension. J Hum Hypertens (1996) 1.04
The Nordic Study on schizophrenic patients living in the community. Subjective needs and perceived help. Eur Psychiatry (2001) 1.02
The validity of Antonovsky's Sense of Coherence measure in a sample of schizophrenic patients living in the community. J Adv Nurs (2001) 1.02
Prediction of later hypertension following a hypertensive pregnancy. J Hypertens Suppl (1983) 1.02
Primary hypertension refractory to triple drug treatment: a study on central and peripheral hemodynamics. Circulation (1978) 1.01
Changes in virulence, M protein and IgG Fc receptor activity in a type 12 group A streptococcal strain during mouse passages. Acta Pathol Microbiol Scand B (1980) 1.01
Psychiatric morbidity in primary public health care: a multicentre investigation. Part II. Hidden morbidity and choice of treatment. Acta Psychiatr Scand (1997) 1.01
Pharmacokinetic studies of metoprolol-(3-h) in the rat and the dog. Acta Pharmacol Toxicol (Copenh) (1975) 1.00
Psychiatric morbidity in primary public health care: a Nordic multicentre investigation. Part I: method and prevalence of psychiatric morbidity. Acta Psychiatr Scand (1995) 1.00
Captopril and atenolol combined with hydrochlorothiazide in essential hypertension. Br J Clin Pharmacol (1982) 1.00
Dose-dependent activation of lymphocytes in endotoxin-induced airway inflammation. Infect Immun (2000) 0.99
Quantitative and qualitative aspects of the social network in schizophrenic patients living in the community. Relationship to sociodemographic characteristics and clinical factors and subjective quality of life. Int J Soc Psychiatry (2001) 0.98
Reproductive history and cigarette smoking as risk factors for thyroid cancer in women: a population-based case-control study. Cancer Epidemiol Biomarkers Prev (1996) 0.98
Gonococcal serovar distribution in Stockholm, with special reference to multiple infections and infected partners. Acta Pathol Microbiol Immunol Scand B (1985) 0.98
Propranolol in hypertension. Report on 158 patients treated up to one year. Klin Wochenschr (1972) 0.97
Controlled trial of nifedipine and bendroflumethiazide in hypertension. J Cardiovasc Pharmacol (1984) 0.96
Patient satisfaction with inpatient psychiatric care. The influence of personality traits, diagnosis and perceived coercion. Acta Psychiatr Scand (1994) 0.96
Clinical and social needs of schizophrenic outpatients living in the community: the relationship between needs and subjective quality of life. Soc Psychiatry Psychiatr Epidemiol (1999) 0.96
Adipose tissue fat cell size and number in relation to metabolism in randomly selected middle-aged men and women. Metabolism (1971) 0.96